Please login to the form below

Not currently logged in
Email:
Password:

Pipeline

This page shows the latest Pipeline news and features for those working in and with pharma, biotech and healthcare.

Biogen and Eisai pull plug on Alzheimer’s drug

Biogen and Eisai pull plug on Alzheimer’s drug

pipeline of potential therapies in Alzheimer’s disease and innovative medicines for patients suffering from diseases of high unmet need.”. ... These failures are already being reflected in a growing pipeline of early stage candidates targeting other

Latest news

More from news
Approximately 14 fully matching, plus 1,632 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    bullet. That is reflected in the diversification of the pipeline. As of January 2018, more than half of phase 3 Alzheimer’s assets were anti-amyloid therapies. ... In phase 2, the figure fell to less than one-third. Data on the early-stage pipeline is

  • Cutting through the noise: CRISPR Cutting through the noise: CRISPR

    There has been a lot of chatter about developing the tool for therapeutic use, and some specialised pharma companies such as Editas already have candidates in the pipeline. ... He adds: “Our hope is that we can bring better validated drug projects into

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Analysts predict the drug could make up to $2bn in peak sales, making it one of the brightest prospects in Shire’s pipeline.

  • Relearning launch: Four key dynamics for pharma launches in 2019 Relearning launch: Four key dynamics for pharma launches in 2019

    2. The pipeline is booming:Drug approvals are on a steady increase globally. ... 3. The science is increasingly more complex:Many of the highest-potential innovations in the pipeline answer unmet needs in largely elusive disease states.

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    A study published earlier this year found that the proportion of pipeline molecules at the unit that moved from preclinical investigation to completion of phase 3 trials rose from 4% to ... She has truly had a significant impact on transforming

More from intelligence
Approximately 1 fully matching, plus 134 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 178 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 33 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics